Read More Pharma Industry News Sobi bets on late-stage gout asset with acquisition of Arthrosi Therapeutics Swedish Orphan Biovitrum is acquiring Arthrosi Therapeutics for $950 million to bolster its inflammation pipeline. Explore what this means for its growth trajectory. bySrinathDecember 14, 2025